Home/Filings/4/0001209191-23-006280
4//SEC Filing

Lloyd-Smith Malcolm 4

Accession 0001209191-23-006280

CIK 0000914475other

Filed

Feb 1, 7:00 PM ET

Accepted

Feb 2, 5:24 PM ET

Size

5.6 KB

Accession

0001209191-23-006280

Insider Transaction Report

Form 4
Period: 2023-01-31
Lloyd-Smith Malcolm
Chief Regulatory Officer
Transactions
  • Sale

    Common Stock

    2023-01-31$110.02/sh1,666$183,29028,582 total
Footnotes (2)
  • [F1]Sale of 1,666 shares of common stock issued upon vesting of 3,164 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,498) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  • [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Issuer

NEUROCRINE BIOSCIENCES INC

CIK 0000914475

Entity typeother

Related Parties

1
  • filerCIK 0001557146

Filing Metadata

Form type
4
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 5:24 PM ET
Size
5.6 KB